Piramals healthcare vertical invests USD $2.5 million to further expand commercial ADC capacity

Specifications:

Name:

Piramals healthcare vertical invests USD $2.5 million to further expand commercial ADC capacity

Location:

UK

Company:

Estimated Cost:

Source:

Piramal’s healthcare vertical invests USD $2.5 million to further expand commercial ADC capacity Piramal’s Healthcare vertical announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand. The upgrade will give Piramal two commercial grade ADC suites at the Grangemouth facility, while retaining clinical phase manufacturing capacity in other suites on site.ADCs are targeted therapies designed to deliver a drug payload to cancer cells while minimising the adverse effects on normal healthy cell and Piramal | Healthcare was the first contract supplier of ADCs globally. The batch size offered from the Grangemouth facility ranges from 1-1.5kg and Piramal has capacity for further expansion on site if required. As part of the investment, the areas supporting the manufacturing suite will also be upgraded to provide new areas for buffer preparation, equipment preparation and antibody freeze / thaw. Piramal also intends to expand its “Proof of Concept” (POC) offer at Grangemouth, for pharma companies looking to demonstrate antibody and/or toxin suitability for use as an ADC. “Piramal was a pioneer when it came to the commercial manufacture of ADCs” commented Aidan Walker, President, Formulation Services. “Continued growth in the ADC market and customer demand have led to this latest investment. As part of our POC offer we draw on our vast experience in ADCs to supply model antibodies, the corresponding target cell lines, and non proprietary toxins, to demonstrate suitability of client materials for use in ADC conjugation. We have worked on over 65 ADC candidates and over 30 different ADC drug linkers to date and also have experience with PEGylation, chelating conjugates for radioimmunotherapy and protein toxin conjugates.” http://www.piramal.com/sites/default/files/pdf/adcs-final3-18072013.pdf Project Name Piramals healthcare vertical invests USD $2.5 million to further expand commercial ADC capacity Location UK Commence 2013 Completion -NA- Estimated Investment $ 2.5 million usd Capacity -NA- Key Players Piramals Healthcare